IRON — Disc Medicine Inc.
NASDAQ · Healthcare · Biotechnology
$78.67
+$0.02 (+0.03%)
Disc Medicine Inc. (IRON) is a biotechnology company listed on NASDAQ. It is led by John D. Quisel Esq., J.D., Ph.D., based in 321 Arsenal Street, Watertown, MA, United States, 02472, with about 154 employees. Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. It also develops preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. The company was founded in 2017 and is headquartered in Watertown, Massachusetts.
Net income was -$62.3M. IRON currently screens at market cap $2.56B.
Use this IRON page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the IRON quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the IRON SEC filings page. Lician reads the product cache first so this HTML stays unique to Disc Medicine Inc. even when a live quote feed is slow.
About Disc Medicine Inc.
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. It also develops preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. The company was founded in 2017 and is headquartered in Watertown, Massachusetts.
IRON Key Statistics
Market Cap
$2.56B
Volume
88,793
Previous Close
$80.94
Day Range
$81.77 – $83.59
EPS
-$3.96
Revenue
$0.00
Net Income
-$109.36M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
154
IRON Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$109.36M | -$76.43M | -$46.83M | -$35.97M |
| EPS (Diluted) | -$3.96 | -$3.42 | -$45.05 | -$40.95 |
Total Assets
$496.77M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$192.43M
Operating Cash Flow
-$93.93M
Free Cash Flow
$0.00
Disc Medicine Inc. Company Information
- CEO, President & Director
- John D. Quisel Esq., J.D., Ph.D.
- Headquarters
- 321 Arsenal Street, Watertown, MA, United States, 02472
- Website
- www.discmedicine.com
- Phone
- 617 674 9274
- IPO / Founded
- 2020-08-12
- Sector
- Healthcare
- Industry
- Biotechnology